Limited access to CD4 tests misses late diagnoses and advanced HIV disease (AHD)
8 August 2025. Related: Conference reports, Treatment strategies, Guidelines, Coinfections and complications.
2025
Induced stress can increase HIV dynamics
7 August 2025. Related: Conference reports, Cure-related research, Basic science and immunology.
Switching to long-acting injectable ART with detectable viral load in people struggling with oral ART
6 August 2025. Related: Antiretrovirals, Treatment strategies, Drug resistance.
Featured IAS 2025: WHO major updates on injectables, AHD, infant feeding and peer support
2 August 2025. Related: Conference reports, Guidelines.
13th IAS Conference on HIV Science (IAS 2025): Introduction and early reports
31 July 2025. Related: Conference reports, Activism & advocacy.
IAS 2025: The Kigali Manifesto on the inclusion of people living with HIV in clinical research
31 July 2025. Related: Conference reports, Treatment access, Coinfections and complications, Cancer and HIV, Activism & advocacy, Research studies.
Latest news on US crisis (24 July): Plans to end PEPFAR
29 July 2025. Related: Treatment access, Activism & advocacy.
IAS 2025: Switching to injectable CAB/RPV-LA with detectable viral load: results from the OPERA cohort
28 July 2025. Related: Conference reports, Antiretrovirals, Treatment strategies.
IAS 2025: Switching to dual ART after durable suppression on triple-drug ART in West and Central Africa
27 July 2025. Related: Conference reports, Antiretrovirals, Treatment strategies.
People living with HIV still excluded from 75% of pivotal cancer studies
27 July 2025. Related: Early access, Cancer and HIV.
IAS 2025: Increases in reports of HIV criminalisation cases globally
26 July 2025. Related: Conference reports, Activism & advocacy.
Plans to transition US HIV treatment guidelines (DHHS)
25 July 2025. Related: Guidelines.
Lenacapavir on track for PrEP approval in Europe: questions on access
25 July 2025. Related: Early access, Antiretrovirals, HIV prevention and transmission.
IAS 2025: Once-weekly oral ART with ulonivirine plus islatravir: 24-week phase 2 results
20 July 2025. Related: Conference reports, Antiretrovirals.
IAS 2025: Reduced dosing could be a safe option for adults: crisis response to ART stock-outs
17 July 2025. Related: Conference reports, Treatment strategies.
IAS 2025: 5-on 2-off dosing is inferior to continuous ART in BREATHER Plus – but no differences in clinical outcomes
17 July 2025. Related: Conference reports, Treatment strategies.
IAS 2025: Long-acting CAB/RPV in people with suboptimal adherence: IMPALA study results at 48 weeks
17 July 2025. Related: Conference reports, Antiretrovirals, Drug resistance.
IAS 2025: Once-monthly oral PrEP using MK-8527: the drug that will stop HIV
17 July 2025. Related: Conference reports, Treatment strategies.
Signal that sliver of PEPFAR might be salvaged
16 July 2025. Related: Treatment access, Activism & advocacy.
IAS 2025: “We will not be erased” – a community Call to Action
15 July 2025. Related: Conference reports, Treatment access, Activism & advocacy.
Call to drop abacavir from use in adults
13 July 2025. Related: Journal scan, Antiretrovirals, Treatment strategies, Coinfections and complications.
IAS 2025: HIV care is political: early focus on the funding crisis
12 July 2025. Related: Conference reports, Treatment access.
IAS 2025: HIV cure research at IAS 2025
12 July 2025. Related: Conference reports.
Global Fund plans for lenacapavir PrEP in selected countries
9 July 2025. Related: Treatment access, HIV prevention and transmission.
Featured AIDS quilts at the Tate: reflection and also anger
8 July 2025. Related: In memory, Early access, Special reports.
US government has altered more than 100 scientific databases since 20 January
5 July 2025. Related: Early access, Treatment alerts, Activism & advocacy.
Latest news on US crisis (3 July): legal challenges, Global Fund, WHO, Kigali conference
5 July 2025. Related: Treatment access, Activism & advocacy.
Phase 2/3 studies put on hold for two once-weekly Gilead compounds
3 July 2025. Related: Antiretrovirals.
UK PrEP 2025 guidelines online
2 July 2025. Related: Guidelines, HIV prevention and transmission.
Why the new HIV PrEP guidelines from the UK are so exciting (2025)
2 July 2025. Related: Special reports, Guidelines, HIV prevention and transmission.
Latest on US crisis (26 June): Global Fund, GAVI and RFK Jr
2 July 2025. Related: Treatment access, Activism & advocacy.
Long-acting injectable PrEP approved in the US: priced at $28,000 a year
1 July 2025. Related: Antiretrovirals, HIV prevention and transmission.
Future meetings and webinars 2025
1 July 2025. Related: Future meetings.
Latest on US crisis (13 June): legal and organisational responses
1 July 2025. Related: Treatment access, Activism & advocacy.
HIV organisations support trans and non-binary communities against the unworkable EHRC guidance
1 July 2025. Related: Treatment access, Activism & advocacy.
Featured UK HIV care for transgender and non-binary people: EHRC guidance is unworkable
1 July 2025. Related: Special reports, Treatment access, Activism & advocacy.
IAS 2025: Kigali Call to Action: sign-on to global leaders
1 July 2025. Related: Conference reports.
UK guidelines on doxyPEP to prevent syphilis and gonorrhoea vaccine to become available in England
17 June 2025. Related: Guidelines, Coinfections and complications.
APBI calls for greater participant diversity in industry studies
15 June 2025. Related: Activism & advocacy, Research studies.
Risk of metabolic syndrome when starting ART with bictegravir vs dolutegravir
7 June 2025. Related: Journal scan, Side effects, Weight, diabetes, metabolic complications.
TAG challenges HIV vaccine cuts as Robert F. Kennedy fires entire CDC vaccine expert advisory panel
6 June 2025. Related: Treatment access, Activism & advocacy, Research studies.
Gates Foundation commits to providing lenacapavir as PrEP next year
3 June 2025. Related: Treatment access, HIV prevention and transmission.
Featured Latest news on the US crisis and its impact on global health
1 June 2025. Related: Journal scan, Special reports, Treatment access, Activism & advocacy.
IAS-USA update drug resistance mutations (2025)
29 May 2025. Related: Guidelines, Drug resistance.
Vaccination is effective in limiting mpox progression – but lower efficacy in people living with HIV
27 May 2025. Related: Journal scan, mpox.
US updates guidelines for statin use in people living with HIV
26 May 2025. Related: Guidelines, Weight, diabetes, metabolic complications.
HIV activists in the US call for action in JID and Zachie Achmat brings South African perspective in the Lancet
26 May 2025. Related: Journal scan, Treatment access, Activism & advocacy.
Combining injectable lenacapavir and cabotegravir-LA
23 May 2025. Related: Journal scan, Antiretrovirals, Treatment strategies, Treatment access.
Scientific, legal and ethical crisis from halting ongoing NIH studies: TAG statement
22 May 2025. Related: Treatment access, Activism & advocacy, Research studies.
Impact of US funding cuts in Malawi and South Africa: ITPC community report
20 May 2025. Related: Treatment access, On the web.
The Denver Principles – riso print by Jane Shepherd to support i-Base
17 May 2025. Related: Special reports.
US CDC updated guidelines on PEP (May 2025)
10 May 2025. Related: Guidelines, HIV prevention and transmission.
Featured Reduced dosing: a possible crisis response to ART stockouts and closed clinics
5 May 2025. Related: Special reports, Antiretrovirals, Treatment strategies, Treatment access.
Closed clinics and limited ART in Zimbabwe, PEPFAR and UNAIDS news
4 May 2025. Related: Treatment access, Activism & advocacy.
Yellow card reporting scheme for doctors and patients in the UK
1 May 2025. Related: Side effects.
The RIO study: Q&A about controlling HIV with bNAbs
21 April 2025. Related: Conference reports, Cure-related research.
Lenacapavir EAP in the UK closed to new referrals: NHS England and Gilead fail to agree a price after more than two years
20 April 2025. Related: Antiretrovirals, Treatment access, Drug resistance, BHIVA news.
CROI 2025: Webcasts and other resources now open access
16 April 2025. Related: Conference reports.
Continued reports from CROI 2025
13 April 2025. Related: Conference reports.
Viral failure on CAB/RPV-LA: overcoming drug resistance with second-generation INSTIs
13 April 2025. Related: Journal scan, Treatment strategies, Drug resistance.
CROI 2025: LAPTOP, EC rebounds after 32 years, two more HSCT cures
12 April 2025. Related: Conference reports, Antiretrovirals, Treatment strategies.
Lancet Commission on gender justice and equality
9 April 2025. Related: Journal scan.
Changes to US policy jeopardises the lives of 500,000 children living with HIV by 2030
8 April 2025. Related: Treatment access.
CROI 2025: Rebecca Denison gives opening community talk on 40 years of HIV
7 April 2025. Related: Conference reports, Activism & advocacy.
Lancet HIV recognises Transgender Day of Visibility and the importance of gender-affirming hormones in HIV care
3 April 2025. Related: Journal scan, Special reports, Treatment access.